Legend Biotech Swings to Q3 Profit: $51.7M Net Income, $359.5M Revenue
LEGN sits 50% above its 52-week low of $16.24.
Summary
Legend Biotech reported Q3 2026 net income of $51.7M ($0.13 per share) on revenue of $359.5M, versus a $39.6M loss a year ago, as CARVYKTI net trade sales grew 36% to about $710M. Cash and time deposits stood at roughly $853M at September 30.
Key Events · Earnings and Guidance · LEGN
-
Q3 Swing to Profit
Net income of $51.7M ($0.13 per diluted share) versus a $39.6M loss in Q3 2025; operating income of $46.8M versus a $43.3M operating loss.
-
CARVYKTI Sales Up 36%
Net trade sales of approximately $710M drove collaboration revenue of $353.2M, up $91.4M year over year; total revenue was $359.5M versus $272.4M.
-
Cost Base Shrinks
R&D fell $17.9M to $95.3M as cilta-cel trial dosing concluded, and administrative expense fell $19.9M to $14.8M on a share-based compensation reversal from forfeited awards.
-
Liquidity and Janssen Advance
Cash and cash equivalents plus time deposits of approximately $853M at September 30, 2026; the Janssen funding advance was cut to $44.1M from $319.1M at December 31, 2025.
Analysis · LEGN · Life Sciences
Profitability arrived on a quarterly basis: operating income of $46.8M versus a $43.3M operating loss a year ago, and net income of $51.7M versus a $39.6M loss. CARVYKTI is the driver, with net trade sales up 36% to roughly $710M pushing collaboration revenue $91.4M higher to $353.2M. Costs moved the right way too — R&D fell $17.9M as the cilta-cel trial dosing phases wound down, and administrative expense dropped $19.9M largely on a share-based compensation reversal from forfeited awards. On the balance sheet, about $853M in cash and time deposits provides comfort, and the Janssen funding advance is down to $44.1M from $319.1M at year-end after non-cash offsets and repayments. The offsetting item is tax: nine-month expense jumped to $21.2M from $3.0M as taxable income rose across the U.S., Belgium and China, and the company is still negotiating an advance pricing agreement with the Chinese Tax Authority, so the final liability could differ materially from what is accrued.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LEGN was trading at $24.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.7B. The 52-week trading range was $16.24 to $37.50. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.